MARK LIGORSKI: Open Payments
NPI 1659465003 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,009 in 47 payments from 13 companies in 2025. Trend: 2023 $862 · 2024 $2,935 · 2025 $1,009
Food & beverage: $1,009
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 9 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $141 |
| ABBVIE INC. | 6 | $138 |
| Neurocrine BioSciences, Inc. | 5 | $120 |
| Corium, LLC | 5 | $91 |
| Teva Pharmaceuticals USA, Inc. | 4 | $85 |
| Tris Pharma Inc | 4 | $75 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Janssen Pharmaceuticals, Inc | 1 | $29 |
Products named: FANAPT, TRINTELLIX, VRAYLAR, INGREZZA, Azstarys, AUSTEDO XR, CAPLYTA, Dyanavel XR.
Industry payments across CT — which companies pay providers there.
